comparemela.com

Latest Breaking News On - Yifan zhai - Page 6 : comparemela.com

ESMO 2023 | Ascentage Pharma to Present Results from Two Clinical Studies, including One Oral Presentation, at 2023 ESMO Congress

/PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and.

Western australiaHong kongAscentage pharmaYuxiang maInnovent biologicsHaibo qiuYifan zhaiMd anderson cancer centerChina national medical products administrationMajor nationalNational reimbursement drug listSun yat sen university cancer centerDana farber cancer instituteEuropean society of medical oncologyMedical oncologyMini oral

Registrational Pivotal Phase III Study of Olverembatinib for the First-Line Treatment of Patients with Ph+ ALL Approved by the CDE in China

/PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and.

United statesHong kongInnovent biologicsAscentage pharmaYifan zhaiPrnewswire ascentage pharmaElias jabbourEuropean unionChinese society of clinical oncologyManufacturing programMd anderson cancer centerChina national medical products administrationDrug administrationDana farber cancer instituteNational reimbursement drug listAmerican society of hematology

Live from ASCO 2023 | Ascentage Pharma Releases the First Dataset of Lisaftoclax in WM, Revealing Encouraging Therapeutic Potential

/PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and.

Hong kongWestern australiaUnited statesPrnewswire ascentage pharmaSikander ailamadhiYifan zhaiAscentage pharmaAmerican society of clinical oncologyChina national medical products administrationNational reimbursement drug listDana farber cancer instituteMd anderson cancer centerMajor nationalPoster presentationAmerican societyClinical oncology

Live from ASCO 2023 | Ascentage Pharma Releases Updated Data Showing APG-2449 s Potential as a New Treatment for Drug-Resistant NSCLC

/PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and.

United statesLi zhangWestern australiaHong kongYifan zhaiAscentage pharmaNational reimbursement drug listAmerican society of clinical oncologySun yat sen university cancer centerChina national medical products administrationMajor nationalMd anderson cancer centerDana farber cancer institutePoster discussionAmerican societyClinical oncology

Live from ASCO 2023 | Updated Data of Olverembatinib in SDH-Deficient GIST including a CBR of 93 8% Signals a Potential Clinical Breakthrough

/PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and.

Hong kongUnited statesWestern australiaInnovent biologicsRuihua xuYifan zhaiAscentage pharmaAmerican society of clinical oncologyMd anderson cancer centerMajor nationalEuropean unionDana farber cancer instituteSun yat sen university cancer centerEuropean medicines agencyAmerican society of hematologyChina national medical products administration

vimarsana © 2020. All Rights Reserved.